Swanson Vitamins Rapid Muscle and Joint Relief with Rhuleave-K

You know how important it is to stay active, whether it’s hitting the gym or your favorite daily activities but you also know what it feels like when you overdo it. When you need fast-acting relief from muscle soreness, try Swanson Rapid Muscle & Joint Relief featuring Rhuleave-K®. Research-backed Rhuleave-K is clinically supported to relieve that muscle and joint soreness in just a few hours 1 so you can keep doing the things you love. Multiple studies indicate Rhuleave-K can quickly soothe stiff muscles throughout the body. 1,2 This botanical formula is also a source of phytoestrogens from turmeric and sesame. This makes it particularly helpful for women both for easing the discomfort of the menstrual cycle 3,4 and helping to balance hormones during the menopausal transition. In relieving physical discomfort, Rhuleave-K can also be a mood booster due in part to the clinically studied supportive properties of curcumin, 5 and also to the simple fact that when your body feels better, you feel better. Plant-based Rhuleave-K is an expertly crafted blend of black sesame seed oil which is cold-pressed to protect delicate phytonutrients, turmeric extract standardized to 26.6% curcuminoids, and Boswellia serrata extract standardized to 1% AKBA (3-O-acetyl-11-keto-β-boswellic acid). Boswellia and turmeric are commonly recommended for muscle and joint discomfort, but have been hampered by poor absorption. Rhuleave-K is formulated using SPEEDTECH™ technology which enhances the bioavailability of the curcumin and boswellia by delivering them in micronized form in a phospholipid-rich base of sesame oil. 2 Sources: (1) Rudrappa GH, et al. Medicine (Baltimore). 2022 Sep 2;101(35):e30144. doi: 10.1097/MD.0000000000030144. (2) Metagenics Institute. 2025. Read Source . (3) Agarwal D, Chaudhary P. J Clin Med. 2023 Jun 11;12(12):3968. doi: 10.3390/jcm12123968. (4) Samira Khayat, et al. Complementary Therapies in Medicine, V23, I3, 2015 (318-324), ISSN 0965-2299, doi: 10.1016/j.ctim.2015.04.001. (5) Lopresti, A.L. CNS Drugs 36, 123–141 (2022). doi: 10.1007/s40263-022-00901-9.